ClinicalTrials.Veeva

Menu
S

Sahlgrenska University Hospital | Gothia Forum - Clinical Trial Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Nivolumab
Cyclophosphamide
Durvalumab
Obeticholic Acid
ATB200
Enzalutamide
Irinotecan Hydrochloride
Norepinephrine
Ipilimumab

Parent organization

This site is a part of Sahlgrenska University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

36 of 312 total trials

A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty

The study is designed to compare three articulation options in terms of osteolysis, patient satisfaction, clinical and radiographic outcomes (Oxford...

Active, not recruiting
Arthritis
Pain
Procedure: Hip Arthroplasty

This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subj...

Enrolling
Metastatic Breast Cancer
HER2 + Breast Cancer
Drug: [177Lu]Lu-ABY-271

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chem...

Enrolling
Colorectal Neoplasms
Biological: Cetuximab
Biological: Amivantamab

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

Active, not recruiting
Hematological Malignancies
Drug: Teclistamab

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Drug: Lecanemab

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Leas...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: Best Available Therapy (BAT)
Drug: INCA034176

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Cyclophosphamide

The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in par...

Enrolling
Muscle Invasive Urothelial Carcinoma
Drug: Autogene Cevumeran
Drug: Nivolumab

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH...

Enrolling
Congenital Adrenal Hyperplasia
Drug: Lu AG13909

This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- d...

Enrolling
Prostate Cancer Metastatic
Drug: Androgen deprivation therapy
Drug: Darolutamide 300 mg

The specific study aim is to determine whether a 12-week digitally delivered behavior change intervention for patients with peripheral artery disease...

Active, not recruiting
Intermittent Claudication
Device: A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease

A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced,...

Enrolling
Cholangiocarcinoma
Drug: Ivosidenib Oral Tablet

This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who ar...

Enrolling
Metastatic Breast Cancer
Procedure: metastatic lesion biopsy

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with...

Enrolling
Advanced Malignancies
T-cell Lymphoma
Drug: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Drug: BI-1808

This is a first-in-human clinical, open label, non-randomized, prospective investigation to assess the initial safety and performance of the COPLA® c...

Active, not recruiting
Cartilage or Osteochondral Defects in the Knee
Device: COPLA® cartilage implant

Trial sponsors

S
V
G
AbbVie logo
Karolinska Institute logo
R
U
S
Janssen (J&J Innovative Medicine) logo
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems